A Multicenter, Open-label, Follow-up Study to Assess the Long-term Use of Lacosamide (Flexible Dose From 200 to 600 mg/Day) Used as Monotherapy in Subjects Who Completed SP0994 and Received Lacosamide Monotherapy Treatment
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Lacosamide (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors UCB
- 15 Feb 2018 Planned End Date changed from 1 Sep 2018 to 1 Nov 2019.
- 15 Feb 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Nov 2019.
- 20 Dec 2016 Status changed from recruiting to active, no longer recruiting.